This image provided by Amylyx Pharmaceuticals shows the drug Relyvrio. The much-debated drug for Lou Gehrig’s disease won approval by the U.S. Food and Drug Administration on Thursday, Sept. 29, 2022, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines. (Amylyx Pharmaceuticals via AP)